Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on March 30, 2023, regarding events occurring on March 29 and March 30, 2023. The filing discloses significant executive leadership changes within the company's research and development division.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Departure of Executive: Briggs W. Morrison, M.D., resigned as President and Head of Research and Development, effective April 15, 2023. He will transition to a three-month consulting role and remains a Class III director.
- Appointment of Executive: Neil Gallagher, M.D., Ph.D., was appointed as the new President and Head of Research and Development, effective April 10, 2023. Dr. Gallagher previously served as Chief Medical Officer at AbbVie and Head of Development at Amgen.
Management Commentary, Risks, and Unusual Items
Compensation and Employment Terms
An employment agreement was entered into with Dr. Gallagher effective March 30, 2023, with the following key terms:
- Base Salary: $530,000 annually.
- Target Bonus: 45% of base salary (pro-rated for 2023).
- Equity Award: Inducement stock option for 250,000 shares. Vesting begins 25% on the one-year anniversary, followed by monthly vesting over 36 months.
- Severance (Termination without Cause/Good Reason): Nine months' base salary, nine months of health insurance, and accelerated vesting of equity that would have vested within 12 months.
- Change in Control Severance: If termination occurs within 3 months prior to or 12 months after a change in control, benefits increase to 12 months' base salary plus 100% of the target bonus, 12 months of health insurance, and full accelerated vesting of all unvested options.
The agreement includes a "gross-up" provision to ensure Dr. Gallagher receives the greater net after-tax payment if severance constitutes a "parachute payment" subject to excise tax under Section 280G of the Code.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price for the 250,000 share option grant to Dr. Gallagher.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Confirm the status of Dr. Morrison's consulting agreement and any potential financial implications of his continued directorship.
- Assess the impact of the leadership transition on the company's ongoing clinical development programs.